BZYR
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to treat cancer. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was founded in 1977 and is based in Houston, Texas.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.00 | $0 | -$823,106 |
| 2025 Q2 | -0.00 | $0 | -$94,907 |
| 2025 Q1 | -0.00 | $0 | -$49,143 |
| 2025 Q4 | -0.00 | $0 | -$46,783 |
| 2024 Q3 | -0.00 | $0 | -$134,120 |
| 2024 Q2 | -0.00 | $0 | -$148,098 |
| 2024 Q1 | -0.00 | $0 | -$59,530 |
| 2024 Q4 | -0.00 | $0 | -$137,620 |